English
French
German
Italian
Russian
Spanish
AstraZeneca halts Phase III trials for kidney disease treatment
AstraZeneca halts Phase III trials for kidney disease treatment By Investing.com
Breaking News
‘;
EditorHari GStock Markets
Published Dec 01, 2023 07:46AM ET
© Reuters.
AstraZeneca (NASDAQ:AZN) plc has announced the discontinuation of its Phase III STABILIZE-CKD and DIALIZE-Outcomes trials, which were investigating treatments for chronic kidney disease (CKD) due to prolonged enrolment periods and low event rates. Despite this setback, the pharmaceutical giant reaffirms its commitment to addressing hyperkalaemia, a condition commonly associated with CKD, through its globally approved potassium binder, Lokelma.
Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, assured that Lokelma maintains a strong safety profile and continues to deliver substantial benefits to patients dealing with hyperkalaemia. The drug is currently approved in 56 countries around the world.
AstraZeneca has also committed to ensuring that patients from the halted trials will continue to receive follow-up care. The company’s CVRM (Cardiovascular, Renal and Metabolism) sector remains focused on advancing treatments that protect organs affected by cardiorenal diseases and is working towards the development of regenerative therapies in this field.
InvestingPro Insights
AstraZeneca’s recent decisions in clinical trials reflect a strategic pivot, but their financial health, as indicated by real-time data from InvestingPro, remains robust. The company’s market capitalization stands at a substantial 199.8 billion USD, showcasing its significant presence in the pharmaceutical industry. Additionally, AstraZeneca boasts an impressive gross profit margin of 89.17% over the last twelve months as of Q3 2023, reflecting efficient operations and strong pricing power.
InvestingPro Tips highlight AstraZeneca’s high earnings quality, with free cash flow exceeding net income, and a high return on invested capital, underscoring the company’s ability to generate profits from its investments. These factors are critical for investors considering the company’s potential for sustained financial performance, especially in light of recent clinical trial updates.
For those looking to delve deeper into AstraZeneca’s financials and future outlook, the InvestingPro platform offers additional insights. There are 18 more InvestingPro Tips available for AstraZeneca, providing a comprehensive analysis of the company’s financial health and market position. With the special Cyber Monday sale, subscribers can now access these valuable tips at a discount of up to 60%, and using the coupon code sfy23 will grant an extra 10% off a 2-year InvestingPro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
AstraZeneca halts Phase III trials for kidney disease treatment
Related Articles
Terms And Conditions
Privacy Policy
Risk Warning
Do not sell my personal information
© 2007-2023 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
